

AnorMED Inc.
Form F-10POS
November 09, 2006

[QuickLinks](#) -- Click here to rapidly navigate through this document

As filed with the Securities and Exchange Commission on November 9, 2006.

Registration No. 333-136931

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**Post-Effective Amendment No. 1
to
Form F-10
REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OF 1933**

ANORMED INC.

(Exact name of Registrant as specified in its charter)

Canada

*(Province or other Jurisdiction of
Incorporation or Organization)*

2834

*(Primary Standard Industrial
Classification Code Number)*

**200 - 20353 64th Avenue
Langley, British Columbia
Canada V2Y 1N5
(604) 530-1057**

(Address and telephone number of Registrant's principal executive offices)

98-0171581

*(I.R.S. Employer Identification
Number, if any)*

CT Corporation System

**111 Eighth Avenue
New York, New York 10011
(212) 894-8600**

(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)

Copies to:

**Paul M. Kinsella
Ropes & Gray LLP
One International Place
Boston, Massachusetts 02110
(617) 951-7000**

**Peter Wirth
Genzyme Corporation
500 Kendall Street
Cambridge, MA 02142
Telephone: (617) 252-7500**

Approximate date of commencement of proposed sale to the public:

Not Applicable

Edgar Filing: AnorMED Inc. - Form F-10POS

Province of British Columbia, Canada
(Principal jurisdiction regulating this offering)

It is proposed that this filing shall become effective (check appropriate box below):

- A. upon filing with the Commission, pursuant to Rule 467(a) (if in connection with an offering being made contemporaneously in the United States and Canada).
- B. at some future date (check appropriate box below)
 - 1. pursuant to Rule 467(b) on () at () (designate a time not sooner than seven calendar days after filing).
 - 2. pursuant to Rule 467(b) on () at () (designate a time seven calendar days or sooner after filing) because the securities regulatory authority in the review jurisdiction has issued a receipt or notification of clearance on ().
 - 3. pursuant to Rule 467(b) as soon as practicable after notification of the Commission by the Registrant or the Canadian securities regulatory authority of the review jurisdiction that a receipt or notification of clearance has been issued with respect hereto.
 - 4. after the filing of the next amendment to this Form (if preliminary material is being filed).

If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to the home jurisdiction's shelf prospectus offering procedures, check the following box.

DEREGISTRATION OF SECURITIES

On August 28, 2006, AnorMED Inc. ("AnorMED") filed a registration statement on Form F-10, Registration No. 333-136931, as amended on September 11, 2006 (the "Registration Statement"), registering the sale by AnorMED from time to time of up to U.S. \$100,000,000 in aggregate of common shares, no par value, of AnorMED ("AnorMED Shares"). On November 7, 2006, Dematal Corp., a wholly-owned subsidiary of Genzyme Corporation, completed a cash tender offer and related transaction pursuant to which it acquired all the outstanding AnorMED Shares.

As AnorMED will cease to be a reporting issuer in connection with this transaction, AnorMED hereby deregisters any and all AnorMED Shares registered under this Registration Statement which have not been issued.

QuickLinks

[DEREGISTRATION OF SECURITIES](#)

[SIGNATURES](#)

[AUTHORIZED REPRESENTATIVE](#)